PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26859293-6	2016	Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells.	Cisplatin	86-95	HCC	Homo sapiens	110-113	
26859293-8	2016	Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin.	Cisplatin	174-183	HCC	Homo sapiens	160-163	
26859293-9	2016	Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients.	Cisplatin	183-192	HCC	Homo sapiens	213-216	
26754678-2	2016	This prospective multicenter trial assessed the efficacy of hepatic arterial infusion chemoembolization therapy with cisplatin suspended in lipiodol combined with 5-fluorouracil for HCC patients with portal vein tumor thrombosis.	Cisplatin	117-126	HCC	Homo sapiens	182-185	
26754678-12	2016	CONCLUSIONS: Hepatic arterial infusion chemoembolization therapy with cisplatin suspension in lipiodol combined with 5-fluorouracil is effective treatment for unresectable HCC with portal vein tumor thrombosis.	Cisplatin	70-79	HCC	Homo sapiens	172-175	
21748762-4	2011	Interestingly, CypB protected tumor cells, even p53-defective HCC cells, against hypoxia- and cisplatin-induced apoptosis.	Cisplatin	94-103	HCC	Homo sapiens	62-65	
31072375-2	2019	Cisplatinum, a well-known chemotherapeutic drug, has been widely used for treatment of numerous human cancers including HCC.	Cisplatin	0-11	HCC	Homo sapiens	120-123	
31072375-3	2019	This study aimed to investigate the differential expressions of LncRNAs in HCC cells treated with cisplatinum and its underlying mechanism.	Cisplatin	98-109	HCC	Homo sapiens	75-78	
31072375-4	2019	METHODS: The differential expressions of LncRNAs in HCC cells treated with cisplatinum were determined by RNA-seq.	Cisplatin	75-86	HCC	Homo sapiens	52-55	
31072375-9	2019	RESULTS: LncRNA TPTEP1 was highly expressed in cisplatinum-treated HCC cells, which sensitizes hepatocellular carcinoma cell to cisplatinum-induced apoptosis.	Cisplatin	47-58	HCC	Homo sapiens	67-70	
31072375-9	2019	RESULTS: LncRNA TPTEP1 was highly expressed in cisplatinum-treated HCC cells, which sensitizes hepatocellular carcinoma cell to cisplatinum-induced apoptosis.	Cisplatin	128-139	HCC	Homo sapiens	67-70	
28219642-1	2017	Cisplatin is a main compound for human hepatocellular carcinoma (HCC) chemotherapies, but it has certain cytotoxicity during applications.	Cisplatin	0-9	HCC	Homo sapiens	39-69	
28219642-4	2017	In order to investigate whether combination usage of RA and cisplatin can be priority to the later drug"s effect development and its toxicity reduction in HCC, both of two drugs were treated 24 h or 48 h in QGY-7703 cells for estimating their abilities in tumor cell proliferation inhibition.	Cisplatin	60-69	HCC	Homo sapiens	155-158	
28219642-9	2017	All these consequences reflect RA plays an important role in enhancing the therapeutic effect of cisplatin in HCC.	Cisplatin	97-106	HCC	Homo sapiens	110-113	
16396674-8	2006	CONCLUSION: Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.	Cisplatin	55-64	HCC	Homo sapiens	176-179	
12138235-8	2002	CONCLUSIONS: Intra-arterial chemotherapy using cisplatin and etoposide seems to have some anti-tumor effect against advanced HCC, although a high rate of life- threatening complications precludes the indication of this regimen at least for patients with non-compensated cirrhosis.	Cisplatin	47-56	HCC	Homo sapiens	125-128